SB 88389th Legislature (2025)
Relating to patient access to prescription drugs for off-label use for COVID-19 treatment.
Progress
- Introduced
- In committee
- Passed Senate
- Passed legislature Not yet
- Sent to governor Not yet
- Became law Not yet
What this bill would cost
-
Fiscal note: Introduced
No significant cost to the state is expected.
Fiscal notes are prepared by the state’s budget staff and reflect the bill as written at the time.
Committee hearings
-
April 1, 2025
Senate Health & Human Services Committee · Left pending in committee
Testified: 3 for, 0 against, 0 on (neutral) · Registered without testifying: 1 for, 1 against, 1 on
- Organizations for
- Make Texans Healthy Again
- Organizations on (neutral)
- Texas Medical Board
-
April 2, 2025
Senate Health & Human Services Committee · Reported favorably w/o amendments
Source: Texas Legislature (Texas Legislative Council). Witness lists show how many people took each position and the organizations they represented; people speaking for themselves are counted but not named here.
Committee votes
- House Public Health · In committee
- Senate Health & Human Services · Out of committee 8 aye, 1 nay
Bill analyses: Introduced
Legislative history
-
House
Referred to Public Health
-
House
Read first time
-
House
Received from the Senate
-
Senate
Reported engrossed
-
Senate
Passed
-
Senate
Read 3rd time
-
Senate
Read 2nd time & passed to engrossment
-
Senate
Record vote
-
Senate
Rules suspended-Regular order of business
-
Senate
Co-author authorized
-
Senate
Placed on intent calendar
-
Senate
Committee report printed and distributed
-
Senate
Reported favorably w/o amendments
-
Senate
Vote taken in committee
-
Senate
Considered in public hearing
-
Senate
Left pending in committee
-
Senate
Testimony taken in committee
-
Senate
Considered in public hearing
-
Senate
Scheduled for public hearing on . . .
-
Senate
Co-author authorized
-
Senate
Referred to Health & Human Services
-
Senate
Read first time
-
Senate
Filed
-
Senate
Received by the Secretary of the Senate